Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Which sedative combo is best for stomach scope procedures?

NCT ID NCT07190612

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested three different drug combinations to sedate patients during upper gastrointestinal endoscopy (a scope procedure to examine the stomach and esophagus). 75 adults were randomly assigned to receive propofol plus either ketamine, dexmedetomidine, or midazolam. Researchers measured how quickly patients woke up and how well they were sedated. The goal is to find the safest and most effective sedation approach for routine endoscopic procedures.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
propofol combined with either ketamine, dexmedetomidine, or midazolam
What this could lead to
If successful, this could help doctors choose the best sedation method for upper GI endoscopy, leading to faster recovery and fewer side effects.
What could go wrong
This is a small, completed Phase 4 trial with only 75 participants, so results may not apply to all patients. The study compares existing drugs, not a new breakthrough.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

75 people

The number who actually took part.

Started

Dec 2024

Finished

Apr 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Both male and female patients aged between 18 and 65 years * Patients who are scheduled for elective upper gastrointestinal endoscopic procedures with sedation * Patients who are classified as ASA (American Society of Anesthesiologists) I and II Exclusion Criteria: * Patient's refusal to participate * Respiratory compromise as patients with respiratory failure or with active chest conditions, e.g., bronchial asthma or pneumonia * Cardiovascular compromise including heart failure and shocked patients * Severe uncontrolled hematemesis with shock or risk of aspiration. * Patients who are allergic or have any contraindications to any of the used drugs. * Patients who have a chronic neuropsychiatric disorder or are on a neuropsychiatric drug. * Patients on long-term sedative medication have a history of drug or alcohol abuse. * Pregnancy and lactation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anesthesia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Faculty of Medicine

    Cairo, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.